Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cloudflare Inc (NET) vs Novo Nordisk A/S (NVO) Price & Performance

Cloudflare IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Cloudflare Inc vs Novo Nordisk A/S — how do they compare? Cloudflare Inc trades at $346.6 (market cap $121.74B), while Novo Nordisk A/S trades at $38.14 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and Novo Nordisk A/S for 116 Days on average.

NETNVO
Market Cap
$121.74B$165.31B
Volume
2,433,00211,432,838
Sector
TechnologyHealth
52-Week High
$359.60$63.98
52-Week Low
$160.16$35.29
Typical Hold Time
61 Days116 Days
Enterprise Value
$121.11B$179.56B
Dividend Yield
—4.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cloudflare Inc

Cloudflare (NET) trades at $342.82, down 3.44% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with $2.17 billion in 2025 sales, though profitability remains challenged with a -8.21% net margin. Recent technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains overwhelmingly positive with 71% buy ratings. The company's recent product launches including Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight ongoing innovation in the connectivity cloud space.

Cloudflare presents a growth story with expanding enterprise adoption but faces valuation concerns at current levels. The stock's premium multiples (P/S 47.88) require continued execution against strong revenue growth targets. Key risks include persistent profitability challenges and competitive pressures in the cloud security market, while catalysts include AI-driven security demand and platform consolidation opportunities.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.

NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NET
61% Buy39% Sell
Avg holding period · 61 Days
NVO
68% Buy32% Sell
Avg holding period · 116 Days

Top news

Latest headlines on both assets

About Cloudflare Inc

Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.

Read more on NET →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →